Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

My 3 top dividend stocks for Christmas

Tucking away some tasty dividends for Christmas can help you to a prosperous New Year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

We’re reaching the end of the year and looking back on a tumultuous one — who, in January, would have put money on the UK voting to leave the EU and Donald Trump winning the US presidential election? And we’re reconsidering our investment strategies in the light of all that, aren’t we?

The one strategy that will surely win out over the long run is seeking high-quality shares paying big dividends. Here are three that I think would be great homes for any leftover 2016 investment cash.

Pharmaceuticals rebound

AstraZeneca (LSE: AZN) has been beefing up its development pipeline after the expiry of key patents brought an end to some previous blockbusters. And while that’s been underway, the dividend has been held unchanged at an attractive level.

More optimistic investors had been hoping to see a return to EPS growth in 2017, though that’s now looking more like 2018. But flat earnings for 2015 and 2016 are actually better than the falls predicted, and the slow pace of drugs approvals means a pipeline turnaround isn’t an overnight thing.

The weak share price performance of the past two years has put the prospective dividend yield at a healthy 5%, way ahead of the FTSE 100 average. It’s covered by earnings, albeit not strongly, and the company will surely not cut it now, so close to the earnings turnaround point.

AstraZeneca looks like a great buy for progressive future dividends once earnings growth resumes.

Cash from insurance

If you want a cash cow, it’s hard to think of a better one than Admiral Group (LSE: ADM).

The motor insurance firm has been paying special dividends for years, handing out a total of 114.4p per share in 2015 for a yield of 6.9% on the year-end share price. The firm also told us it has distributed at least 90% of each year’s earnings as dividends since flotation, and that this year it will adjust its dividend balance. That means bigger ordinary dividends and smaller specials, with the same overall effect but perhaps lifting confidence a little.

Analysts expect 6.7% this year and 6.8% next, although boosted a little above earnings by the firm’s ongoing return of surplus capital.

Over the longer term, I expect to see total yields of 5% to 6% per year at today’s share price levels, and that’s got to be worth having — especially from a UK-only business that looks safe from Brexit.

Reliable oil

My third pick is good old reliable Royal Dutch Shell (LSE: RDSB) with its consistent dividends all through the oil price crisis. Bob Dudley of BP said we could be in for at least two or three years of cheap oil, which turned out to be right, and his key message was simply not to panic as things would be back to normal over the long term.

And while smaller oil companies, especially those carrying big debts, have suffered, BP and Shell have been largely untroubled.

Earnings at Shell have dropped for four years in a row, and won’t come close to covering this year’s dividend. But Shell has the cash to keep on paying it, and with a couple of years of recovering earnings forecast now that the OPEC agreement is lifting the price of a barrel again, cover should be back next year.

And a dividend yield of 6.4% is one that’s surely not to be missed.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Royal Dutch Shell. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

It’s the most popular UK stock in 2025 but hasn’t grown in 5 years! What’s going on?

Harvey Jones is baffled by the sheer popularity of this UK stock. Its shares have hardly grown in recent years…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Dividend Shares

How much do you need in a FTSE 250 portfolio to target £2,147 in monthly income?

Jon Smith runs through the steps needed to build up a generous dividend portfolio and outlines why the FTSE 250…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

2 stocks I wouldn’t touch with a bargepole today in my ISA and SIPP

The following two stocks have a history of being incredibly popular with retail investors. So why is this writer avoiding…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

£10,000 to invest? I asked ChatGPT if it would work harder in a Stocks and Shares ISA or SIPP and it said…

Harvey Jones calls on artificial intelligence to exmaine whether it makes more sense to invest for retirement inside a Stocks…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

No savings at 40? Use Warren Buffett’s golden rule to potentially build a £12,000 second income

Following Warren Buffett’s approach, I’ve learned how disciplined investing can grow a passive income – but only if hidden risks…

Read more »

Investing Articles

With silver soaring to $60, the Fresnillo share price is turning into a runaway express train

Fresnillo is the FTSE 100’s runaway leader in 2025. With silver surging past $60, can its share price keep defying…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

From hero to zero: are Lloyds shares a ticking time-bomb after a 70% gain in 2025?

In 2025, Lloyds shares have produced around 10 years’ worth of average stock market gains. Could they be heading for…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Which stock market is best: the UK or US? Here’s how British investors can benefit regardless

Stock market diversification helps spread risk and capitalise on growth and income. Mark Hartley considers the options for British investors.

Read more »